Merck Obtains EU Positive Opinion for Expanded Use of HIV Drug

Merck Sharp & Dohme, a subsidiary of Merck & Co, has received a positive opinion from the Committee for Medicinal Products for Human Use recommending expanded marketing authorization for Isentress in combination with other antiretroviral medicinal products for the treatment of HIV-1 infection in all appropriate adult patients, including patients starting HIV therapy for the first time, as well as treatment-experienced patients.

The positive opinion will be reviewed by the European Commission, which grants marketing authorization to the 27 countries that are members of the EU, as well as Iceland and Norway.



Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Trump wants more mental health care; Alabama says it's trying